Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Should Big Pharma Buy Into the Medical Marijuana Industry?

By Motley Fool Staff - Dec 6, 2014 at 3:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two Motley Fool analysts share there competing views on whether or not big drugmakers should jump into the medical marijuana market.

Source: Flickr user Mark

Few stories were as captivating to investors as medical marijuana in 2014. The promise of using marijuana to treat common conditions like cancer pain and uncommon indications like epilepsy created a flurry of investor interest that sent shares in marijuana stocks soaring.

However, just because medical marijuana's use is intriguing doesn't mean that these companies will deliver on investor's optimism. Most marijuana drugmakers are small companies that may struggle to come up with the financing necessary to usher treatments through expensive clinical trials. That could suggest that they need to ink licensing deals or be acquired by big pharmaceutical or biotechnology companies. Whether or not big drugmakers would be interested in pursuing such opportunities is an important question, so we asked two Motley Fool analysts for their opinion. Read on to learn whether they think big cap companies should buy into the medical marijuana industry.

Brian Orelli: Should big pharma get into the medical Pacific yew tree industry? How about medical poppy business?

Trick question. They already are.

Bristol-Myers Squibb's ( BMY 1.64% ) cancer drug Taxol was discovered in the Pacific yew tree. Opiate pain killers such as morphine and codeine are found in opium poppy. There are plenty of other examples of useful drugs that were derived from plants as well.

It's pretty clear there are useful chemicals -- cannabinoids called CBD and THC -- in marijuana. GW Pharmaceuticals' ( GWPH ) Sativex, which is a mixture of CBD and THC, is approved in a few countries to treat spasticity in patients with multiple sclerosis and cancer and its CBD-based drug candidate Epdiolex appears to be helping pediatric epilepsy patients without any other options.

There are certainly risks associated with cannabinoids, but for indications where there's a high risk of death and no other options, the risks become secondary to the benefits.

I don't see any inherent reason why big pharma shouldn't be trying to study the same pathways except for the stigma of marijuana. Companies could get around the issue by synthesizing the active compound directly rather than deriving it from the plant. AbbVie's ( ABBV 1.69% ) Marinol, for instance, is synthetic THC, which is FDA approved to increase appetites of patients with AIDS and is also used off-label for cancer patients.

Leo Sun: Investing in medical marijuana doesn't make sense for the biggest pharma companies because it's simply not that profitable.

For example, GW Pharmaceuticals' ( GWPH ) flagship cannabinoid medicine, Sativex, has been approved or recommended for approval in 24 countries as a treatment for severe spasticity caused by multiple sclerosis. Despite that impressive geographic reach, Sativex only generated £3.4 million ($5.3 million) in revenues in the first nine months of fiscal 2014.

GW's pipeline of treatments includes drugs targeting potential type 2 diabetes and schizophrenia indications. While there are a number of interesting opportunities in its pipeline, it's still too early and unproven for me to feel confident in its pricey valuation -- over 20x trailing-12 month revenue.

And with cannabinoid drugs like Sativex not selling well, combined with pricey valuations for current so-called 'marijuana stocks', I don't see a compelling reason for big pharma to throw money into acquiring these drugs or their developers. Big pharma needs, well, big revenue streams to move the needle -- and these cannabinoid drugs just haven't provided that, at least not yet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$56.32 (1.64%) $0.91
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$118.85 (1.69%) $1.98
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.